The U.S. Food and Drug Administration (FDA) already declared that shortages of popular GLP-1 medications have ended, CNN ...

In patients with T2D, GLP-1s don’t increase the risk for acute pancreatitis, mitigate the risk for complications in those who ...

Widely used GLP-1 drugs for type 2 diabetes such as Novo Nordisk's Ozempic may modestly reduce the risk of obesity-related ...

The findings add to other research showing a lower risk of obesity-related cancers in patients taking GLP-1 drugs, a class of ...

For people trying to quit smoking, use of a GLP-1 receptor agonist may help prevent weight gain, a common barrier to quitting ...

After questions and criticism online, Janelle Rohner says she should have disclosed her decision to take a GLP-1.

Newly recognized issues, including extreme fatigue with excessive weight reduction, bone loss, and abdominal pain, point to ...

GLP-1 receptor agonists may reduce risk for obesity-related cancers among people with diabetes compared with dipeptidyl ...

If you're one of the millions of Americans who have used or thought about using GLP-1 weight-loss drugs, it’s important to ...

Novo Nordisk's limited-time coupon on Wegovy was simultaneously promoted by telehealth companies Ro and Wegovy ...

Dr. Rubinstein has years of experience working with patients to help them achieve their desired goals in a realistic, ...

The agreements cap monthly out-of-pocket costs for Zepbound and Wegovy at $200 and more deeply discount the drugs for ...